Spanning regulatory and commercial realms, DRG brings to you 4 strategy recommendations that medtech firms can’t ignore in 2020

  • The topics selected reflect key drivers of the evolving medtech commercial landscape and consider impacts on patients as well as the cost of doing business
  • The recommendations are based on input from DRG’s medtech experts, including analysts, data experts, consultants, account managers, and executives and considered customer requests, secondary research, report research & data analysis
  • While the events and macrotrends affecting these strategies will unfold over years, the focus of this piece is on actions that medtech firms can take in 2020

A look ahead: Medical aesthetics market recovery in 2021 and beyond

View Now